News about Biotechnology

Glenmark Pharma launches generic Banzel tablets

Glenmark Pharmaceuticals has launched rufinamide tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel tablets, 200 mg and 400 mg of Eisai. Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for rufinamide tablets USP, 200 mg and 400 mg, with a paragraph IV certification and received final approval

Biotechnology | 01/06/2021 | By Darshana |  202

Dyadic enters collaboration with Syngene to develop Covid-19 vaccine

Dyadic International, Inc. (Dyadic), a global biotechnology company, has entered into a collaboration with Syngene International Limited (Syngene), an integrated research, development, and manufacturing services company, to develop a Covid-19 vaccine candidate that can protect against the emerging variants of concern

Biotechnology | 27/05/2021 | By Darshana |  238

Lupin announces achievement of key milestones for its clinical stage MEK inhibitor compound

Global pharma major Lupin Limited announced the achievement of key milestones for Lupin's MEK inhibitor compound (LNP3794) that is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult-to-treat cancers

Biotechnology | 27/05/2021 | By Darshana |  384

Glenmark Pharma receives US FDA approval for generic Firazyr injection

Glenmark Pharmaceuticals Limited has received final approval by the United States Food & Drug Administration (FDA) for icatibant injection, 30 mg/3 mL (10 mg/mL) single-dose prefilled syringe, the generic version of Firazyr injection, 30 mg/3 mL (10 mg/mL) single-dose prefilled syringe, of Shire Human Genetic Therapies, Inc

Biotechnology | 24/05/2021 | By Darshana |  244

MSN Labs launches posaconazole to treat black fungus

MSN Laboratories has launched posaconazole in India under the brand name PosaOne as 100 mg delayed release tablets & 300 mg injections respectively. Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients

Biotechnology | 21/05/2021 | By Darshana |  221

To expand reach in gene therapy, Gamma Biosciences buys controlling stake in Wisconsin-based Mirus Bio

Gamma Biosciences, a global life sciences company serving the advanced therapy market, announced that it has agreed to make a controlling investment in Mirus Bio, an innovator and developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Madison, Wisconsin

Biotechnology | 19/05/2021 | By Darshana |  208

BD to Build New Manufacturing Facility in Spain of euro 165-million Pre-Filled Drug Delivery Business and will create up to 600 jobs by 2030

BD to Build New Manufacturing Facility in Spain of Euro165 Million Pre-Filled Drug Delivery Business, the new facility will be the fourth manufacturing plant for BD in Spain. The site will initially have a workforce of 150 people and encompass an area of 8,000 square meters (86,000 square feet). By 2030 it is expected to

Biotechnology | 18/05/2021 | By Hemant |  282

MagBio develops automated RNA purification chemistry on Thermofisher KingFisher Flex

Mawi DNA Technologies LLC, a biotechnology company, announced that MagBio Genomics has successfully developed an automated RNA purification method for iSWAB-RNA v2 on the Thermofisher KingFisher Flex platform with its HighPrep Total RNA Isolation Kit - iSWAB

Biotechnology | 13/05/2021 | By Darshana |  508

In its Fight Against Pandemic, FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents

The FDA has updated the Fact Sheets for Healthcare Providers Administering the Vaccine (Vaccination Providers) and for Recipients and Caregivers with information to reflect the use of the vaccine in the adolescent population, including the benefits and risks of the Pfizer-BioNTech COVID-19 Vaccine.

Biotechnology | 12/05/2021 | By Hemant |  1551

LANXESS disinfectant kills coronavirus SARS-CoV-2 in just 60 seconds

Rely+On Virkon achieved rapid and complete inactivation of the SARS-CoV-2 virus at a dilution ratio of 1:100 in just 60 seconds, and at an economical 1:600 in-use dilution with a 10 minute contact time.

Biotechnology | 04/09/2020 | By Hemant |  492